Bristol-Myers Squibb Co.

NYSE:BMY   3:59:59 PM EDT
-0.18 (-0.28%)
4:23:20 PM EDT: $64.81 -0.05 (-0.08%)

Bristol-Myers Says On April 29, Will Meet With An FDA Committee To Discuss Opdivo Hepatocellular Carcinoma U.S. Indication

Published: 03/11/2021 23:41 GMT
Bristol-Myers Squibb Co. (BMY) - Bristol-myers Squibb Co - Statement on Opdivo (nivolumab) Hepatocellular Carcinoma U.S. Indication.
Bristol-myers Squibb Co - on April 29, Will Meet With an FDA Committee to Discuss Hepatocellular Carcinoma Indication for Opdivo Monotherapy.